- Oops!Something went wrong.Please try again later.
Zimmer Biomet ZBH has been gaining from the gradual stabilization of the global musculoskeletal market. The Dental and Spine Spin-Off plan bodes well for the company. The better-than-expected results for the first quarter and bullish 2021 guidance provided by the company buoy optimism as well. However, stiff competition and pricing continue to remain major headwinds.
Over the past six months, this Zacks Rank #3 (Hold) stock has gained 12.2% versus 6.4% growth of the industry and 16% rise of the S&P 500.
The renowned musculoskeletal healthcare provider has a market capitalization of $34.9 billion. The company projects 8.9% growth for the next five years and expects to maintain strong segmental performance. Further, it delivered an earnings surprise of 48.75%, on average, over the trailing four quarters.
Let’s delve deeper.
Key Growth Catalysts
Solid Q1 Results: Despite challenging market conditions in the form of pricing pressure, the company witnessed gradual stability in the global musculoskeletal market with better-than-expected revenues and earnings growth in the first quarter of 2021. Core hip and S.E.T. business registered growth in the reported quarter. Operating margin expansion was another upside. The current full-year guidance and strong revenue growth expectations buoy optimism as well.
Gradually Stabilizing Market: Zimmer Biomet has been witnessing gradual stability in the global musculoskeletal market over the last few quarters with better-than-expected sales growth in certain geographies on improved procedural volume. This was driven by favorable demographics and growing utilization of musculoskeletal healthcare in emerging markets and under-penetrated developed markets. With its expectation that the market will stabilize further, Zimmer Biomet is confident about its differentiated portfolio that comprises both premium and value-based offerings.
Dental and Spine Spin-Off Plan Bodes Well: According to Zimmer Biomet management, the planned spin-off of its Spine and Dental business is part of the company’s third phase of ongoing transformation, which includes changing the complexion of the business through active portfolio management in order to accelerate growth and drive value creation. Per management, for Zimmer Biomet, the transaction is an important step in the company’s transition into a more streamlined organization with focus on greater and more optimized resource allocation toward innovation in core businesses that are profitable and where it sees attractive markets with opportunities to become market leaders.
Pricing Pressure Persists: Pricing continues to be a major headwind for Zimmer Biomet. The company's top-line growth in the reported quarter was partially offset by continued pricing pressure, mostly in the Americas and Europe operating segments.
Competitive Landscape: The presence of a large number of players has made the medical devices market intensely competitive. The orthopedic industry in particular is highly competitive with the presence of players like Stryker, Johnson & Johnson's DePuy, Smith & Nephew and Medtronic.
Zimmer Biomet has been witnessing a positive estimate revision trend for 2021. Over the past 30 days, the Zacks Consensus Estimate for its earnings per share (EPS) has moved 2.1% north to $7.81.
The Zacks Consensus Estimate for its second-quarter fiscal 2021 EPS is pegged at $1.83, suggesting a stupendous surge of 3560% from the year-ago reported number.
A few better-ranked stocks from the broader medical space are National Vision Holdings, Inc. EYE, Owens & Minor, Inc. OMI and Envista Holdings Corporation NVST, each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
National Vision has a projected long-term earnings growth rate of 23%.
Owens & Minor has a projected long-term earnings growth rate of 15%.
Envista Holdings has an estimated long-term earnings growth rate of 26%.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency have sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Owens & Minor, Inc. (OMI) : Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report
National Vision Holdings, Inc. (EYE) : Free Stock Analysis Report
Envista Holdings Corporation (NVST) : Free Stock Analysis Report
To read this article on Zacks.com click here.